(1H-benzoimidazol-2-yl)-(3,4-dichlorobenzyl)amine | 332357-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (1H-benzoimidazol-2-yl)-(3,4-dichlorobenzyl)amine
• 英文别名: N-[(3,4-dichlorophenyl)methyl]-1H-benzimidazol-2-amine
• CAS: 332357-62-7
• 化学式: C₁₄H₁₁Cl₂N₃
• 分子量: 292.167
• InChiKey: CZPFDBASOLMDDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (E)-N-(1H-1,3-benzodiazol-2-yl)-1-(3,4-dichlorophenyl)methanimine 在 甲醇 、 sodium tetrahydroborate 作用下， 反应 3.0h， 以73%的产率得到(1H-benzoimidazol-2-yl)-(3,4-dichlorobenzyl)amine
  参考文献：
  名称：

  2-氨基苯并咪唑衍生物及其合成和应用

  摘要：

  本发明涉及一种化合物，具体涉及一种2‑氨基苯并咪唑衍生物及其合成工艺，其具有杀菌活性。2‑氨基苯并咪唑衍生物，其结构式I为：其中R为F、Cl、Br、OH或CH3；制备方法包括有以下步骤：S1)以2‑氨基苯并咪唑为起始原料在催化剂作用下经与取代芳香醛在反应溶剂存在下反应得到中间体N‑苯并咪唑基‑取代苯基亚胺，S2)N‑苯并咪唑基‑取代苯基亚胺经还原得到2‑取代苄基苯并咪唑。本发明的有益效果在于：本发明合成2‑氨基苯并咪唑衍生物工艺简单，结构新颖，采用菌丝生长速率法测定目标化合物对病原菌菌丝的生长抑制作用，发现部分化合物具有较高的杀菌活性，具有较大的发展潜力。

  公开号：

  CN110256359A

文献信息

• Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels
  申请人：Sorensen Ulrik Svane

  公开号：US20080200529A1

  公开（公告）日：2008-08-21

  This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

  本发明涉及一种新型2-氨基苯并咪唑衍生物，可用作小通量钙激活钾通道（SK通道）的调节剂。在其他方面，本发明涉及将这些化合物用于治疗方法以及包含本发明化合物的制药组合物。
• NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS
  申请人：Sørensen Ulrik Svane

  公开号：US20100280087A1

  公开（公告）日：2010-11-04

  This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

  本发明涉及新颖的2-氨基苯并咪唑衍生物，其可用作小电导钙激活钾通道（SK通道）的调节剂。在其他方面，本发明涉及使用这些化合物的方法进行治疗，并且涉及包含本发明化合物的制药组合物。
• Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels.
  申请人：NeuroSearch AS

  公开号：EP2319512A1

  公开（公告）日：2011-05-11

  This invention relates to novel 2-amino benzimidazole derivatives of formula (Ia) and (Ib) useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

  本发明涉及新型的式(Ia)和(Ib)2-氨基苯并咪唑衍生物，可作为小电导钙激活钾通道（SK 通道）的调节剂。 在其他方面，本发明涉及这些化合物在治疗方法中的用途以及包含本发明化合物的药物组合物。
• Synthesis and Structure−Activity Relationship Studies of 2-(N-Substituted)-aminobenzimidazoles as Potent Negative Gating Modulators of Small Conductance Ca²⁺-Activated K⁺ Channels
  作者：Ulrik S. Sørensen、Dorte Strøbæk、Palle Christophersen、Charlotte Hougaard、Marianne L. Jensen、Elsebet Ø. Nielsen、Dan Peters、Lene Teuber

  DOI：10.1021/jm800809f

  日期：2008.12.11

  Small conductance Ca2+-activated K+ channels (SK channels) participate in the control of neuronal excitability, in the shaping of action potential firing patterns, and in the regulation of synaptic transmission. SK channel inhibitors have the potential of becoming new drugs for treatment of various psychiatric and neurological diseases such as depression, cognition impairment, and Parkinson's disease. In the present study we describe the structure-activity relationship (SAR) of a class of 2-(N-substituted)-2-aminobenzimidazoles that constitute a novel class of selective SK channel inhibitors that, in contrast to classical SK inhibitors, do not block the pore of the channel. The pore blocker apamin is not displaced by these compounds in binding studies, and they still inhibit SK channels in which the apamin binding site has been abolished by point mutations. These novel SK inhibitors shift the concentration-response curve for Ca2+ toward higher values and represent the first example of negative gating modulation as a mode-of-action for inhibition of SK channels. The first described compound in this class is NS8593 (14), and the most potent analogue identified in this study is the racemic compound 39 (NS11757), which reversibly inhibits SK3-rnediated currents with a K-d value of 9 nM.
• US7842817B2
  申请人：——

  公开号：US7842817B2

  公开（公告）日：2010-11-30